BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rahne KE, Tagesson C, Nyholm D. Motor fluctuations and Helicobacter pylori in Parkinson’s disease. J Neurol. 2013;260:2974-2980. [PMID: 24002418 DOI: 10.1007/s00415-013-7089-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Testerman TL, Morris J. Beyond the stomach: an updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. World J Gastroenterol. 2014;20:12781-12808. [PMID: 25278678 DOI: 10.3748/wjg.v20.i36.12781] [Cited by in CrossRef: 138] [Cited by in F6Publishing: 114] [Article Influence: 23.0] [Reference Citation Analysis]
2 Mulak A, Bonaz B. Brain-gut-microbiota axis in Parkinson's disease. World J Gastroenterol 2015;21:10609-20. [PMID: 26457021 DOI: 10.3748/wjg.v21.i37.10609] [Cited by in CrossRef: 248] [Cited by in F6Publishing: 207] [Article Influence: 49.6] [Reference Citation Analysis]
3 van Kessel SP, El Aidy S. Contributions of Gut Bacteria and Diet to Drug Pharmacokinetics in the Treatment of Parkinson's Disease. Front Neurol 2019;10:1087. [PMID: 31681153 DOI: 10.3389/fneur.2019.01087] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
4 Lewitt PA. Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics: Levodopa Pharmacokinetics and Pharmacodynamics. Mov Disord 2015;30:64-72. [DOI: 10.1002/mds.26082] [Cited by in Crossref: 132] [Cited by in F6Publishing: 109] [Article Influence: 18.9] [Reference Citation Analysis]
5 Moustafa SA, Mohamed S, Dawood A, Azar J, Elmorsy E, Rizk NAM, Salama M. Gut brain axis: an insight into microbiota role in Parkinson's disease. Metab Brain Dis 2021. [PMID: 34370175 DOI: 10.1007/s11011-021-00808-2] [Reference Citation Analysis]
6 Çamcı G, Oğuz S. Association between Parkinson's Disease and Helicobacter Pylori. J Clin Neurol 2016;12:147-50. [PMID: 26932258 DOI: 10.3988/jcn.2016.12.2.147] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 9.6] [Reference Citation Analysis]
7 McGee DJ, Lu XH, Disbrow EA. Stomaching the Possibility of a Pathogenic Role for Helicobacter pylori in Parkinson's Disease. J Parkinsons Dis 2018;8:367-74. [PMID: 29966206 DOI: 10.3233/JPD-181327] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 14.5] [Reference Citation Analysis]
8 Smeyne RJ, Noyce AJ, Byrne M, Savica R, Marras C. Infection and Risk of Parkinson's Disease. J Parkinsons Dis 2021;11:31-43. [PMID: 33361610 DOI: 10.3233/JPD-202279] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Lahner E, Virili C, Santaguida MG, Annibale B, Centanni M. Helicobacter pylori infection and drugs malabsorption. World J Gastroenterol. 2014;20:10331-10337. [PMID: 25132749 DOI: 10.3748/wjg.v20.i30.10331] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
10 Dardiotis E, Tsouris Z, Mentis AA, Siokas V, Michalopoulou A, Sokratous M, Dastamani M, Bogdanos DP, Deretzi G, Kountouras J. H. pylori and Parkinson's disease: Meta-analyses including clinical severity. Clin Neurol Neurosurg. 2018;175:16-24. [PMID: 30308319 DOI: 10.1016/j.clineuro.2018.09.039] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 13.7] [Reference Citation Analysis]
11 Huang HK, Wang JH, Lei WY, Chen CL, Chang CY, Liou LS. Helicobacter pylori infection is associated with an increased risk of Parkinson's disease: A population-based retrospective cohort study. Parkinsonism Relat Disord. 2018;47:26-31. [PMID: 29174171 DOI: 10.1016/j.parkreldis.2017.11.331] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
12 Tan AH, Lim S, Mahadeva S, Loke MF, Tan JY, Ang BH, Chin KP, Mohammad Adnan AF, Ong SMC, Ibrahim AI, Zulkifli N, Lee JK, Lim WT, Teo YT, Kok YL, Ng TY, Tan AGS, Zulkifle IM, Ng CK, Ee SS, Arafin S, Mohamad Shukori K, Vadivelu JS, Marras C, Fox SH, Lang AE. Helicobacter pylori Eradication in Parkinson's Disease: A Randomized Placebo‐Controlled Trial. Mov Disord 2020;35:2250-60. [DOI: 10.1002/mds.28248] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
13 Pfeiffer R. Beyond here be dragons: SIBO in Parkinson’s disease. Mov Disord. 2013;28:1764-1765. [PMID: 24167009 DOI: 10.1002/mds.25705] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
14 Elfil M, Kamel S, Kandil M, Koo BB, Schaefer SM. Implications of the Gut Microbiome in Parkinson's Disease. Mov Disord 2020;35:921-33. [DOI: 10.1002/mds.28004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 27.0] [Reference Citation Analysis]
15 Alvarez-Arellano L, Maldonado-Bernal C. Helicobacter pylori and neurological diseases: Married by the laws of inflammation. World J Gastrointest Pathophysiol. 2014;5:400-404. [PMID: 25400983 DOI: 10.4291/wjgp.v5.i4.400] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 35] [Article Influence: 6.1] [Reference Citation Analysis]
16 Fasano A, Visanji NP, Liu LWC, Lang AE, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. The Lancet Neurology 2015;14:625-39. [DOI: 10.1016/s1474-4422(15)00007-1] [Cited by in Crossref: 349] [Cited by in F6Publishing: 149] [Article Influence: 58.2] [Reference Citation Analysis]
17 Pfeiffer RF, Isaacson SH, Pahwa R. Clinical implications of gastric complications on levodopa treatment in Parkinson's disease. Parkinsonism Relat Disord 2020;76:63-71. [PMID: 32461054 DOI: 10.1016/j.parkreldis.2020.05.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
18 Freitas ME, Hess CW, Fox SH. Motor Complications of Dopaminergic Medications in Parkinson's Disease. Semin Neurol 2017;37:147-57. [PMID: 28511255 DOI: 10.1055/s-0037-1602423] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
19 Hayes MW, Fung VS, Kimber TE, O'sullivan JD. Updates and advances in the treatment of Parkinson disease. Medical Journal of Australia 2019;211:277-83. [DOI: 10.5694/mja2.50224] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
20 Nyholm D, Hellström PM. Effects of Helicobacter pylori on Levodopa Pharmacokinetics. J Parkinsons Dis 2021;11:61-9. [PMID: 33164946 DOI: 10.3233/JPD-202298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
21 Dézsi L, Vécsei L. Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs. Expert Opinion on Drug Metabolism & Toxicology 2014;10:409-24. [DOI: 10.1517/17425255.2014.878702] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]